The ascendancy of Viagra and its impact on the pharmaceutical landscape presents a intricate question for shareholders. While the initial sales figures were astounding, the patent has expired, leading to a wave of generic alternatives that are eroding earnings. In addition, the industry is facing issues related to aging trends and changing healt… Read More